Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07575230

Suzetrigine vs Norco-postoperative Mohs Pain

To compare suzetrigine versus hydrocodone/acetaminophen for postoperative pain control following dermatologic surgery.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Cutaneous Tumors Mohs Micrographic Surgery Neoplasms Neoplasms by Site Skin Diseases Skin Neoplasms Skin and Connective Tissue Diseases

Age range

18 year–89 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Baylor University Medical Center

Dallas, Texas, 75246, United States

About this study

This study is a randomized, controlled trial that is evaluating the safety and efficacy of suzetrigine as a postoperative pain medication compared to the standard of care Hydrocodone/Acetaminophen in patients undergoing Mohs micrographic surgery (MMS) who are at high-risk for postoperative pain and opioid use. The goal is to reduce opioid prescription use and give patients a non-opioid pain medication option for particularly painful surgeries. Patients will be randomized into one of two groups, one group will receive the interventional medication and the other the standard of care medication.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • adults between the age of 18-89
  • individuals who have a cutaneous tumor treated by MMS

Exclusion criteria

  • individuals younger than 18 and older than 89
  • individuals taking medications that interact with the CYP3A (Cytochrome P450 3A) pathway
  • individuals with liver disease

Treatment and study plan

Norco 5Mg-325Mg Tablet

Drug

Standard of care drug

Suzetrigine

Drug

Control Drug

Primary outcomes

  1. Change in need for opioid medication for pain management after Mohs micrographic surgery

    Time frame: 48hours post surgery

    Change in mean visual analog scale (VAS; 0-10) pain scores at 24 and 48 hours after surgery with a minimal change in pain score of 1.0 points.

Secondary outcomes

  1. Patient-reported adequacy of pain control

    Time frame: 48hours post surgery

    Assessment of pain control with use of medication following surgery.

  2. Rescue pain management use

    Time frame: 48hours post surgery

    Changes in need to use rescue medication for pain management

  3. Adverse Events

    Time frame: 3 days after surgery

    Evaluation of occurence of adverse events (irregular heart beat, abnormal blood pressure, change in consciousness, or need for urgent care or emergency room visit in the first 3 days after surgery).

Sponsors and collaborators

Lead sponsor

Baylor Research Institute

Other

Registry information

Official study title

Non-Opioid Pain Management After Mohs Reconstruction: An Investigator-Initiated, Prospective, Randomized Clinical Trial of Suzetrigine vs Hydrocodone/Acetaminophen

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
May 8, 2026
Registry last updated
May 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.